Shionogi & Co. Ltd.

In News

Shionogi & Co: Acquisition Of All Rights To Radicava (Edaravone) Is Expected To Be Immediately Accretive In Fiscal Year 2026, Adding Approximately USD $700 Million In Annual Global Sales - TradingView

TradingView - Apr 01, 2026

Shionogi Seals $2.5 Billion RADICAVA Deal to Build Rare Disease Franchise - TipRanks

TipRanks - Apr 02, 2026

Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) - PharmiWeb.com

PharmiWeb.com - Apr 02, 2026

GSK, Pfizer and Shionogi finalize changes to ViiV Healthcare ownership - Investing.com

Investing.com - Apr 01, 2026

Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109 - PR Newswire

PR Newswire - Mar 24, 2026

Shionogi & Co: acquisition of all rights to Radicava (edaravone) is expected to be immediately accretive in fiscal year 2026, adding approximately USD $700 million in annual global sales - MarketScreener

MarketScreener - Apr 01, 2026

Tanabe Pharma America Announces Finalization of RADICAVA (Edaravone) Transfer to Shionogi - Moomoo

Moomoo - Apr 01, 2026

Shionogi pays Apnimed $100M for sleep disorder joint venture - Fierce Biotech

Fierce Biotech - Mar 24, 2026

Pfizer exits ViiV as GSK (NYSE: GSK) keeps 78.3% stake, Shionogi grows - Stock Titan

Stock Titan - Apr 01, 2026

Shionogi to buy out Apnimed stake in sleep apnea venture for up to USD$150 million - Mugglehead Magazine

Mugglehead Magazine - Mar 29, 2026

A Look At Shionogi (TSE:4507) Valuation After Recent Share Price Momentum - Yahoo Finance

Yahoo Finance - Mar 27, 2026

Shionogi enrols first patients in Esprit trial for Pompe disease - Clinical Trials Arena

Clinical Trials Arena - Mar 20, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment